The Potential of the Nutraceutical Berberine in the Treatment of Hepatocellular Carcinoma and Other Liver Diseases Such As NAFLD and NASH
Overview
Molecular Biology
Authors
Affiliations
Hepatocellular carcinoma (HCC) is a common cancer which unfortunately has poor outcomes. Common anti-cancer treatments such as chemotherapy and targeted therapy have not increased patient survival significantly. A common treatment for HCC patients is transplantation, however, it has limitations and complications. Novel approaches are necessary to more effectively treat HCC patients. Berberine (BBR) is a nutraceutical derived from various fruits and trees, which has been used for centuries in traditional medicine to treat various diseases such as diabetes and inflammation. More recently, the anti-proliferation effects of BBR have been investigated in the treatment of patients with various cancers, especially colorectal cancer, and in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this review, we will focus on studies with BBR in liver diseases.
Fang R, Sha C, Xie Q, Yao D, Yao M Anticancer Agents Med Chem. 2024; 25(2):75-85.
PMID: 39313900 DOI: 10.2174/0118715206301453240910044913.
Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome.
Rong J, Zhang Z, Peng X, Li P, Zhao T, Zhong Y Int J Biol Sci. 2024; 20(12):4783-4798.
PMID: 39309427 PMC: 11414397. DOI: 10.7150/ijbs.100394.
Duda-Madej A, Viscardi S, Szewczyk W, Topola E Int J Mol Sci. 2024; 25(15).
PMID: 39125943 PMC: 11313295. DOI: 10.3390/ijms25158375.